Wu Yuzhong, Xie Zengshuo, Liang Weihao, Xue Ruicong, Wu Zexuan, Wu Dexi, He Jiangui, Zhu Wengen, Liu Chen
Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
NHC Key Laboratory of Assisted Circulation, Sun Yat-sen University, Guangzhou, 510080, China.
ESC Heart Fail. 2021 Apr;8(2):1369-1377. doi: 10.1002/ehf2.13217. Epub 2021 Jan 27.
Coexisting of atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF) could increase the risk of mortality. In this study, we aimed to assess the values of the CHADS2, R2CHADS2, and CHA2DS2-VASc scores for AF prediction in HFpEF patients.
We performed a retrospective analysis on symptomatic HFpEF patients in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial. Associations of the CHADS2, R2CHADS2, and CHA2DS2-VASc scores with the risk of incident AF in HFpEF patients without baseline AF (n = 2202) were assessed using the multivariable competing risk regression models. The discriminatory performances of these scores were calculated using the C-index. During a median follow-up of 3.3 years, the average incidence of AF was 1.80 per 100 patient-years in HFpEF patients. When score was analysed as a continuous variable, per 1-point increase in the CHADS2 (hazard ratio [HR] = 1.42, 95% confidence interval [CI]: 1.20-1.68, C-index: 0.71), R2CHADS2 (HR = 1.25, 95% CI: 1.10-1.42, C-index: 0.69), or CHA2DS2-VASc (HR = 1.30, 95% CI: 1.16-1.46, C-index: 0.70) scores was associated with an increased risk of incident AF. When score was analysed as a categorical variable, patients with CHADS2 ≥ 3 (HR = 2.62, 95% CI: 1.70-4.04), R2CHADS2 ≥ 3 (HR = 2.55, 95% CI: 1.56-4.17), or CHA2DS2-VASc ≥ 4 (HR = 2.54, 95% CI: 1.59-4.07) had a higher risk of incident AF compared with the corresponding controls.
Our data first suggest that the CHADS2, R2CHADS2, and CHA2DS2-VASc scores could predict the risk of incident AF in HFpEF patients with modest predictive abilities.
射血分数保留的心力衰竭(HFpEF)患者合并心房颤动(AF)会增加死亡风险。在本研究中,我们旨在评估CHADS2、R2CHADS2和CHA2DS2-VASc评分在预测HFpEF患者发生AF方面的价值。
我们对TOPCAT(醛固酮拮抗剂治疗射血分数保留的心力衰竭)试验中有症状的HFpEF患者进行了回顾性分析。使用多变量竞争风险回归模型评估CHADS2、R2CHADS2和CHA2DS2-VASc评分与无基线AF的HFpEF患者(n = 2202)发生AF风险的相关性。使用C指数计算这些评分的鉴别性能。在中位随访3.3年期间,HFpEF患者AF的平均发生率为每100患者年1.80例。当将评分作为连续变量分析时,CHADS2评分每增加1分(风险比[HR]=1.42,95%置信区间[CI]:1.20-1.68,C指数:0.71)、R2CHADS2评分(HR = 1.25,95%CI:1.10-1.42,C指数:0.69)或CHA2DS2-VASc评分(HR = 1.30,95%CI:1.16-1.46,C指数:0.70)与发生AF的风险增加相关。当将评分作为分类变量分析时,CHADS2≥3(HR = 2.62,95%CI:1.70-4.04)、R2CHADS2≥3(HR = 2.55,95%CI:1.56-4.17)或CHA2DS2-VASc≥4(HR = 2.54,95%CI:1.59-4.07)的患者与相应对照组相比,发生AF的风险更高。
我们的数据首次表明,CHADS2、R2CHADS2和CHA2DS2-VASc评分可预测HFpEF患者发生AF的风险,预测能力中等。